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Abstract 
Background: The most recent (2012) worldwide estimates from International Agency for Research 
on Cancer indicate that approximately 528,000 new cases and 270,000 deaths per year are 
attributed to cervical cancer worldwide. The disease is preventable with HPV vaccination and with 
early detection and treatment of pre-invasive cervical intraepithelial neoplasia, CIN. Antibodies 
(Abs) to HPV proteins are under investigation as potential biomarkers for early detection.  
Methods: To detect circulating HPV-specific IgG Abs, we developed programmable protein arrays 
(NAPPA) that display the proteomes of two low-risk HPV types (HPV6 and 11) and ten oncogenic 
high-risk HPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52 and 58). Arrays were probed with sera 
from women with CIN 0/I (n=78), CIN II/III (n=84), or invasive cervical cancer (ICC, n=83).  
Results: Abs to any early (E) HPV protein were detected less frequently in women with CIN 0/I 
(23.7%) than women with CIN II/III (39.0%) and ICC (46.1%, p<0.04). Of the E Abs, anti-E7 Abs 
were the most frequently detected (6.6%, 19.5%, and 30.3%, respectively). The least frequently 
detected Abs were E1 and E2-Abs in CIN 0/I (1.3%) and E1-Abs in CIN II/III (1.2%) and ICC (7.9%). 
HPV16-specific Abs correlated with HPV16 DNA detected in the cervix in 0% of CIN 0/I, 21.2% of 
CIN II/III, and 45.5% of ICC. A significant number (29 – 73%) of E4, E7, L1, and L2 Abs had 
cross-reactivity between HPV types.  
Conclusion: HPV protein arrays provide a valuable high-throughput tool for measuring the 
breadth, specificity, and heterogeneity of the serologic response to HPV in cervical disease. 
Key words: Antibodies; HPV; cervical cancer; cervical intraepithelial neoplasia; NAPPA; protein microarrays; 
serology; early detection 
Introduction 
Human papillomaviruses (HPV) are a family of 
more than 200 closely related viruses with small (8 kb) 
circular double-stranded genomes. The virus is 
restricted to epithelial surfaces where it induces a 
non-lytic cellular proliferation and minimal 
immunologic response. The estimated number of new 
cases of cervical cancer worldwide was 528,000 in 
2012, with an annual global mortality rate of 270,000 
deaths [1, 2]. Vaccines preventing infection are highly 
effective for the prevention of type-specific cervical 
and anogenital cancer precursors (vaginal, vulvar, 
anal), may reduce relapse after conization [3], but are 
not a treatment for pre-existing HPV infection. 
Vaccines are expected to substantially reduce the 
burden of HPV-associated cancers. In the US, even 
with low vaccine coverage, vaccination has resulted in 
a 64% reduction in the prevalence of types 6, 11, 16, 
and 18 among females aged 14 to 19 years and 34% 
decrease among those aged 20- 24 years [4]. 
The epidemiology and natural history of HPV 
infection has been best characterized in the cervix 
where precursor lesions are well recognized, using 
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detection of HPV DNA or detection of antibodies 
(Abs) to HPV as biomarkers of disease pathogenesis 
[5]. Genital HPV is usually acquired shortly after 
sexual debut, and prevalence is highest in adolescents 
and young adults [4, 6, 7]. Cervical cancer is a rare 
consequence of this common infection, with ~50% of 
the cases worldwide caused by the HPV16 type. 
While high risk (HR) HPV infection is considered 
necessary for cervical carcinogenesis, additional 
factors are clearly involved. A small fraction of 
infected women gradually progress to invasive 
cancer, following a long, histologically well-defined 
pre-invasive phase (cervical intraepithelial neoplasia; 
CIN), ranging from low grade (CIN I) to high grade 
(CIN II and III) [8]. Cervical cancer is preventable 
because high grade lesions are detectable by clinical, 
histopathologic, or molecular alterations and can be 
surgically removed [9]. Current clinical practice in the 
US relies on regular screening with cytology (Pap test) 
often combined with HR HPV nucleic acid testing to 
refer women for colposcopy and biopsy. Recent data 
have documented that cytology screening is 
associated with a significantly reduced incidence and 
risk of death from cervical cancer, with odds ratios 
ranging from 0.28 to 0.60 [10, 11], despite a reported 
high false negative rate [12]. Cytologic screening 
remains subject to sampling errors, problems with 
cellular preservation, and reader subjectivity. 
Biomarkers are needed in particular to aid in the 
selection of patients for colposcopy screening in 
resource-limited settings in low and middle income 
countries (LMICs), where nucleic acid and cytology 
testing are cost-prohibitive. Efforts are underway by 
the World Health Organization and the Program for 
Appropriate Technology in Health (PATH) to 
generate cost-effective HPV DNA testing [13]. 
Measuring the humoral immune response to 
HPV antigens (Ags) has been integral to 
understanding the natural history of infection and 
efficacy of vaccination [8, 14, 15]. Despite the potential 
of HPV serology in disease diagnosis and prognosis, 
its clinical application has been limited by HPV 
heterogeneity, assay variability, and viral immune 
evasion. HPV has a limited repertoire of proteins, 
grouped as early (E1, E2, E4, E5, E6, E7) and late (L1, 
L2) proteins. The late proteins form the viral protein 
coat during productive infections. The early proteins 
interact with host and viral proteins to maintain viral 
replication. The serologic response to genital HPV 
infection is primarily directed at conformational 
epitopes on the viral major capsid protein L1. As the 
infection is non-lytic, the host Ab response to L1 is 
weak and may persist for years, as an indication of 
past infection but not malignancy [16, 17]. Although 
anti-L1 Abs are an indication of past infection, only 50 
– 70% of infected women seroconvert [18, 19].  
Abs to both HPV16 E6 and E7 proteins have been 
detected at low levels in both serum and 
cervical-vaginal secretions of invasive cervical cancer 
(ICC) patients [20]. Their levels increase with cervical 
disease progression but they are not detectable in a 
subset of patients with cervical cancer [16, 21-23]. 
They develop later in the course of ICC, and are 
correlated with disease outcome [21, 24, 25]. Studies of 
sera collected prior to the diagnosis of cervical cancer 
have shown that the presence of E6 and E7-specific 
Abs is associated with an increased relative risk 
(RR=2.7) for cervical cancer, and can be detected, 
albeit infrequently, up to 5 years prior to diagnosis 
[26]. The percentage of women with false negative 
serology is dependent on the method of Ab detection 
[16, 27-31].  
The diverse array of oncogenic HPV types and 
the technical limitations of high throughput protein 
expression and display have been impediments to 
HPV immune profiling and most research has focused 
on select Ags from the most common viral types [16, 
21, 28]. Nucleic Acid Programmable Protein Arrays 
(NAPPA) [32, 33] have enabled rapid profiling of the 
serum Ab response in the settings of infections [34, 
35], autoimmune diseases [36, 37] and cancer [38-40]. 
To measure the serologic responses across multiple 
HPV types, we adapted NAPPA for the detection of 
HPV-specific IgG Abs in sera [41]. Full length cDNAs 
encoding the proteomes of 12 HPV types are 
expressed as C-terminal GST fusion proteins using 
mammalian in vitro transcription/translation, and 
captured onto a glass slide surface [42]. In a pilot 
study, we demonstrated that HPV protein arrays 
display immunogenic epitopes that can be detected 
using HPV-specific monoclonal Abs (MAbs) and with 
select sera from HPV-specific malignancies [41]. The 
purpose of this study was to systematically 
investigate the serologic immune profile to HPV in 
women with high-grade pre-invasive cervical lesions 
and ICC, and to identify serologic biomarkers for 
diagnosis and early detection of cervical cancer.  
Materials and methods 
Sample selection 
We used the Biorepository for Molecular 
Signatures of Cervical Cancer developed by the 
Centers for Disease Control and Prevention as a 
Clinical Epidemiology and Validation Center for 
NCI’s Early Detection Research Network (EDRN). 
Samples in the biorepository were collected from 
women attending colposcopy clinics at urban public 
hospitals in Atlanta, GA, Detroit, MI, or Galveston, TX 
between 2000 and 2010 and linked to epidemiologic 
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and clinical data, including HPV detected in 
exfoliated cervical cells, age, race, and tissue 
confirmation of cervical disease status [43]. For this 
study, 162 samples from women with cervical 
intraepithelial neoplasia (CIN) grade 0 (no CIN), I, II, 
III were selected, of which 78 were CIN 0/I and 84 
were CIN II/III. We used 83 archived anonymized 
plasma samples from women with ICC collected in 
Atlanta, GA prior to 1997. For convenience, the term 
serum is used throughout the manuscript. While HPV 
vaccine history was not collected, HPV vaccination 
was not introduced before 2006, and it is unlikely that 
any study participants were vaccinated. Only a subset 
(n=51) of the ICC samples had information on the 
HPV DNA status of the tumor, of which 24 (47.1%) 
were HPV16+. Samples were collected using a 
standardized sample collection protocol and stored at 
-80°C until use. Written informed consent was 
obtained from all subjects under institutional review 
board approval.  
HPV microarray generation and detection of 
serum antibodies 
Production of custom HPV protein arrays and 
array quality control experiments were performed as 
previously reported [41] with modifications described 
here. In brief, arrays displaying codon-optimized 
proteomes of 2 low risk (HPV6 and 11) and 10 high 
risk (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, and 58) HPV 
types were generated. The codon-optimized HPV16 
L1 gene previously used [41] was replaced with the 
non-codon-optimized version, which had higher 
protein expression. Both codon-optimized and 
non-optimized HPV16 E6 and E7 were printed on the 
arrays for direct comparison of Ab reactivity. Since 
only the non-codon optimized HPV16 E6 and HPV16 
E7 [41] showed immunoreactivity, only those results 
are shown. All non-codon-optimized genes were 
obtained by nested PCR using gene-specific primers 
from HPV16 plasmid DNA (American Type Culture 
Collection, Manassas, VA) as described [44]. All genes 
were inserted into pDONR221 vector per 
manufacturer’s instructions (Invitrogen, Carlsbad, 
CA), and were converted to the pANT7_cGST vector 
(http://dnasu.asu.edu/DNASU/Home.jsp)[32]. 
Human IgG and the C-terminal portion of the 
Epstein-Barr virus-derived Ag EBNA-1 were used as 
positive controls. A set of non-HPV related negative 
control proteins (n=93) were printed on the arrays and 
used for array signal intensity normalization and 
establishment of cut-off values. Arrays were 
incubated with serum samples diluted 1:50 in 10% E. 
coli lysate prepared in 5% milk-PBST (0.2% tween) [45] 
and serum Ab detection was performed as previously 
described [38, 41, 44, 46].  
Protein array image analysis and quantification 
After serum binding and IgG detection, arrays 
were scanned by Tecan PowerScanner (Tecan Group, 
Männedorf, Switzerland). ArrayPro Analyzer version 
6.3 (MediaCybernetics, Bethesda, MD) was used to 
measure the signal intensity of individual spots on the 
scanned slides. Normalization of raw intensity values 
was performed by subtracting the slide background 
signal and dividing by the background signal 
subtracted from the median intensity of all spots. The 
slide background signal was determined by the first 
quartile of signal intensity of the no-DNA control 
spots (all material except DNA). In addition, array 
images were qualitatively inspected to identify and 
confirm positive responses by adjusting raw images to 
extreme brightness and contrast using ArrayPro 
Analyzer and visual analysis of diffused signal (ring) 
as described previously [34, 40]. Each spot was scored 
based on the intensity and morphology of the ring on 
a scale of 0 to 5. 
HPV DNA detection by L1 consensus PCR 
For all the samples from the biorepository, HPV 
DNA was detected in extracts of exfoliated cervical 
cells collected in PreservCyt media as previously 
described [43]. Briefly, 16 ml of the PreservCyt 
collection media was extracted using MasterPure 
Complete DNA and RNA purification kit (Epicentre, 
Madison, WI). HPV detection and typing was 
performed using the Roche linear array that detects 37 
types. HPV results for the anonymized archived 
cervical cancer cases (n=83) were based on combined 
results of colorimetric ISH for HPV16, 18, 31, 33, 35 on 
formalin-fixed paraffin embedded tissue sections and 
L1 consensus PCR with MY09/11 primers and 
type-specific hybridization to 6 HR types (16, 18, 31, 
33, 35, 45) on DNA extracts from the same tissues 
(methods in use at the time of archiving [47]).  
Statistical analysis 
The correlation of raw signal intensities of 
protein expression between the arrays randomly 
selected for quality control was determined with 
scatter plots and the Pearson correlation coefficient 
(R) was calculated to assess consistency. Levels of 
protein expression on the arrays were measured by 
calculating the mean values of raw signal intensities 
of duplicate spots from two arrays. For serum Ab 
reactivity on protein arrays, mean values (of duplicate 
spots for a given Ag) of normalized signal intensity 
were compared for different disease groups using 
Fisher’s exact test (Graphpad Prism version 5.0c, San 
Diego, CA). A p-value of <0.05 was considered 
significant. Seropositivity for any given Ag was 
defined as the median of normalized signal intensity 
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values of all negative control proteins (n=93) in all 
sera (n=234) +3 standard deviations or spots that were 
positive by visual analysis. A total of 245 serum 
samples were tested on the arrays, of which 11 (4.5%; 
n=7 ICC, n=4 CIN) were excluded from the analysis 
due to high background. High array background was 
defined as an array with normalized signal intensity 
values for ≥14 out of 93 negative control spots 
exceeding the 75th percentile + 1.5*interquartile range 
of this negative control protein across all arrays.  
Results 
Characteristics of study samples 
Our primary goal was to determine the 
prevalence and specificity of HPV-specific Ab 
responses in women with cervical cancer precursors 
and with ICC. Age, race, and HPV DNA status of 
patients contributing samples to the study are shown 
in Table 1. Ab levels were compared in women with 
CIN 0/I (n=78) and CIN II/III (n=84) who were 
referred to colposcopy because of abnormalities in 
cervical cancer screening, and in women with ICC 
(n=83). Women with CIN 0/I were chosen as the 
relevant control population to determine the utility of 
these biomarkers within a high-risk population. As 
expected, women with CIN 0/I had a lower frequency 
of cervical high-risk (HR) HPV than women with CIN 
II/III (57.7% vs. 97.6%, p<0.0001). Infection with 2 or 
more HPV types was detected in more than 35% of 
women in both CIN 0/I and CIN II/III (Table 1). 
Women with CIN II/III were as expected significantly 
younger than women with ICC (mean 30.0 yrs vs. 52.0 
yrs, p<0.0001). There was also a lower frequency 
(p<0.0015) of HPV16 in CIN 0/I (19.2%) than CIN 
II/III (63.1%) and ICC (47.1%). The clinics 
participating in the EDRN study had a high 
proportion of minority and Hispanic white patients. 
The racial distribution of the samples occurred by 
chance. 
Production and reproducibility of NAPPA 
HPV protein arrays 
The quality and reproducibility of the array 
printing were evaluated by picogreen staining of 
DNA and measuring protein expression with 
anti-GST Abs (Supplemental Figure 1A). Three 
arrays were printed on each slide and the correlation 
coefficients of anti-GST signal intensities were 
determined for intra-array (R=0.98) and intra-batch 
replicate arrays (R=0.90) from two subarrays on the 
same slide or two randomly selected slides within the 
print batch (Supplemental Figure 1B).  
HPV-specific antibody prevalence 
There was no significant difference (p=0.46) in 
the percentages of negative control spots (displaying 
the non-HPV related proteins; n=93) that exceeded the 
cut-off value between arrays probed with CIN 0/I 
(0.71%), CIN II/III (0.81%), and ICC (1.77%) sera.  
The prevalence of HPV-specific serum IgG Abs 
among women with CIN 0/I, CIN II/III, and ICC is 
summarized in Table 2. At least one of the 
HPV-specific Abs was detected in serum from women 
with CIN 0/I (46.1%), CIN II/III (59.8%), and ICC 
(68.4%). Abs to any early (E) HPV protein were 
detected more frequently in women with ICC (46.1%) 
and CIN II/III (39.0%) than women with CIN 0/I 
(23.7%, p<0.04). Abs to any L1 protein had the highest 
prevalence (28.9%, 34.1%, and 44.7% in CIN 0/I, CIN 
II/III, and ICC, respectively). Of the E Abs, anti-E7 
Abs were the most frequently detected (CIN 0/I, 
6.6%; CIN II/III, 19.5%; and ICC, 30.3%). The least 
frequently detected Abs were E1 and E2-Abs in CIN 
0/I (1.3%) and E1-Abs in CIN II/III (1.2%) and ICC 
(7.9%). The sensitivity [proportion of cases with at 
least one HPV Ag-specific Ab detected] was 
comparable when restricted to cases known to have 
HPV16 (as opposed to any other oncogenic HPV) 
DNA detected; 59.6% vs 59.8% for CIN II/III and 
81.8% vs 68.4% for ICC, (p-value N.S.). Among all 
women (irrespective of HPV DNA status), Abs to 
HPV16 Ags were detected in only 6.6%, 19.5%, and 
35.5% in CIN 0/I, CIN II/III, and ICC, demonstrating 
the importance of multi-antigenic immunoprofiling. 
 
Table 1. Characteristics of Study Samples. 
Characteristics Disease Status 
CIN 0/I 
N = 78 
CIN II/III 
N = 84 
ICC 
N = 83 
N (%) N (%) N (%)* 
Age in yrs, Mean 28.7  30.0   52.0 
 < 30 51 (65.3) 45 (53.6) 3/79 (3.8) 
 ≥ 30 27 (34.6) 39 (46.4) 76/79 (96.2) 
Race    
 Black  71 (91.0) 55 (65.5) 64/79 (81.0) 
 Other 7 (9.0) 29 (34.5) 15/79 (19.0) 
HPV16 DNA status†    
 HPV16+ 15 (19.2) 53 (63.1) 24/51 (47.1) 
HPV DNA status 
overall† 
   
 Negative 23 (29.5) 2 (2.4) 12/51 (23.5) 
 1 HPV type 29 (37.2) 46 (54.8) 39/51 (76.5) 
 2 HPV types 10 (12.8) 19 (22.6) 0/51 (0) 
 ≥ 3 HPV types 16 (20.5) 17 (20.2) 0/51 (0) 
 Any HR HPV‡ 45 (57.7) 82 (97.6) 39/51 (76.5) 
*N varies for each category because of missing information. The numbers of 
samples are shown.  
†HPV testing methods used for anonymized archived samples differed from those 
used in biorepository, so results are not directly comparable.  
‡The following HPV types were considered as high-risk types for this analysis 
-HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 
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Table 2. Prevalence of positive antibody response (1) to each HPV protein from any HPV type (2). 
 No. + (%) 
 CIN 0/I CIN II/III ICC Total 
 Total HPV16+(3) Total HPV16+(3) Total HPV16+(3)  
HPV Antibodies N=76 N=14 N=82 N=52 N=76 N=22(4)  
E1 1 (1.3) 0 (0) 1 (1.2) 0 (0) 6 (7.9)* 1 (4.5) 8 (3.4) 
E2 1 (1.3) 0 (0) 4 (4.9) 1 (1.9) 11 (14.5) 5 (22.7) 16 (6.8) 
E4 5 (6.6) 0 (0) 14 (17.1) 5 (9.6) 12 (15.8) 4 (18.2) 31 (13.2) 
E5 5 (6.6) 1 (7.1) 4 (4.9) 3 (5.8) 12 (15.8) 6 (27.3) 21 (9.0) 
E6 3 (3.9) 0 (0) 8 (9.8) 5 (9.6) 12 (15.8)* 5 (22.7) 23 (9.8) 
E7 5 (6.6) 0 (0) 16 (19.5)* 10 (19.2) 23(30.3)* 8 (36.4)* 44 (18.8) 
Any E (2) 18 (23.7) 2 (14.3) 32 (39.0)* 19 (36.5) 35 (46.1)* 15 (68.2)* 85 (36.3) 
L1 22 (28.9) 4 (28.6) 28 (34.1) 16 (30.8) 34 (44.7) 12 (54.5) 84 (35.9) 
L2 8 (10.5) 0 (0) 5 (6.1) 5 (9.6) 13 (17.1) 6 (27.3) 26 (11.1) 
Any L (2) 25 (32.9) 4 (28.6) 32 (39.0) 20 (38.5) 38 (50.0) 14 (63.6)* 95 (40.6) 
Any E and/or L(2) 35 (46.1) 4 (28.6) 49 (59.8) 31 (59.6) 52 (68.4)* 18 (81.8)* 136 (58.1) 
Any HPV16 Ag 5 (6.6) 0 (0) 16 (19.5)* 11 (21.2) 27 (35.5)* 10 (45.5)* 48 (20.5) 
(1) Cut-off values defined as the median of normalized signal intensity values of all negative control proteins +3 standard deviations in all sera (n=234) or spots that were 
positive by visual analysis. 
(2) Any positive vs. all negative from any of the 12 HPV types tested. 
(3) HPV16 DNA detected in cervix. HPV testing methods used for anonymized archived samples differed from those used in biorepository. 
(4) HPV DNA status was known for only a subset (n=51) of the ICC samples. 
* p<0.05, compared with CIN 0/I 
 
Type-specific antibody response 
To determine whether patients with a specific 
HPV infection develop type-specific Abs, there are 
multiple challenges. First, a significant number of 
women with CIN have multiple HPV types detected 
(33.3% of CIN 0/I and 42.8% of CIN II/III, Table 1), 
and past exposure to other HPV types cannot be 
excluded. Second, there is likely serologic 
cross-reactivity across HPV types. Figure 1A shows 
Abs from an ICC patient reacting with E4 protein 
from 4 different HPV types (16, 31, 35, and 45). As 
examples, Figures 1B and 1C show serum from two 
women with CIN II/III with HPV16 DNA and Abs 
against HPV16 E4 and HPV52 E4 (B) and HPV 58 E4 
(C).  
To determine whether there is any correlation 
between HPV DNA types detected in the patient and 
type-specific serum Abs, we analyzed the data in two 
ways. In Table 3A, subjects were stratified based on 
cervical HPV DNA status. For example, among 
women with successful Ab testing, cervical HPV16 
DNA was detected in 18.4% of those with CIN 0/I; 
63.4% of CIN II/III; and 46.8% of ICC. The 
type-specific Ab detection rate in this group was 0%, 
21.2%, and 45.5% for CIN 0/I, CIN II/III and ICC. For 
the most common HPV DNA detected in cervical 
samples in CIN II/III, HPV16, 31, 35, and 52, the range 
of detection of type-specific Abs was 8.3 – 25.0%. In 
Table 3B, subjects were stratified by type-specific 
seropositivity to evaluate the proportion with 
detection of type-specific HPV DNA in the cervix. 
Women with HPV16 Abs and CIN II/III had the 
highest type-specific DNA detection, 78.6%, followed 
by HPV31 (36.4%), 45 (25.0%), and 52 (14.2%).  
 
Table 3A. Prevalence of HPV type-specific IgG Abs in women with known cervical HPV DNA status.  
 
 
 
HPV DNA in cervix 
 No. + (%) 
Total Number(1) CIN 0/I 
N=76 
CIN II/III 
N=82 
ICC 
N=47(2) 
 Total Ab+(3) Total Ab+(3) Total Ab+(3) 
HPV6 3 1 (1.3) 0 (0) 2 (2.4) 0 (0) 0 (0) 0 (0) 
11 2 1 (1.3) 0 (0) 1 (1.2) 0 (0) 0 (0) 0 (0) 
16 88 14 (18.4) 0 (0) 52 (63.4) 11 (21.2) 22 (46.8) 10 (45.5) 
18 16 3 (3.9) 1 (33.3) 5 (6.1) 1 (20.0) 8 (17.0) 2 (25.0) 
31 20 2 (2.6) 0 (0) 16 (19.5) 4 (25.0) 2 (4.3) 0 (0) 
33 10 2 (2.6) 0 (0) 5 (6.1) 0 (0) 3 (6.4) 1 (33.3) 
35 16 5 (6.6) 2 (40.0) 10 (12.2) 2 (20.0) 1 (2.1) 1 (100.0) 
39 5 3 (3.9) 1 (33.3) 2 (2.4) 1 (50.0) 0 (0) 0 (0) 
45 10 5 (6.6) 1 (20.0) 5 (6.1) 1 (20.0) 0 (0) 0 (0) 
51 7 4 (5.3) 1 (25.0) 2 (2.4) 0 (0) 1 (2.1) 0 (0) 
52 21 9 (11.8) 1 (11.1) 12 (14.6) 1 (8.3) 0 (0) 0 (0) 
58 14 10 (13.2) 1 (10.0) 3 (3.7) 0 (0) 1 (2.1) 0 (0) 
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Table 3B. Prevalence of type-specific HPV DNA in women with known seropositivity.  
 
 
 
HPV -specific Abs 
Total Number(4) No. + (%) 
CIN 0/I 
N=76 
CIN II/III 
N=82 
ICC 
N=76(2) 
Total DNA+(5) Total DNA+(5) Total DNA+(5) 
HPV6 24 4 (5.3) 0 (0) 10 (12.2) 0 (0) 10 (13.2) 0 (0) 
11 25 5 (6.6) 0 (0) 8 (9.8) 0 (0) 12 (15.8) 0 (0) 
16 46 5 (6.6) 0 (0) 14 (17.1) 11 (78.6) 27 (35.5) 10 (37.0) 
18 50 11 (14.5) 1 (9.0) 15 (18.3) 1 (6.7) 24 (31.6) 2 (8.3) 
31 37 5 (6.6) 0 (0) 11 (13.4) 4 (36.4) 21 (27.6) 0 (0) 
33 58 14 (18.4) 0 (0) 18 (22.0) 0 (0) 26 (34.2) 1 (3.8) 
35 78 21 (27.6) 2 (9.5) 19 (23.2) 2 (10.5) 38 (50.0) 1 (2.6) 
39 51 10 (13.2) 1 (10.0) 20 (24.4) 1 (5.0) 21 (27.6) 0 (0) 
45 26 5 (6.6) 1 (20.0) 4 (4.9) 1 (25.0) 17 (22.4) 0 (0) 
51 24 5 (6.6) 1 (20.0) 6 (7.3) 0 (0) 13 (17.1) 0 (0) 
52 31 5 (6.6) 1 (20.0) 7 (8.5) 1 (14.2) 19 (25.0) 0 (0) 
58 18 4 (5.3) 1 (25.0) 5 (6.1) 0 (0) 9 (11.8) 0 (0) 
(1) of women with the corresponding HPV DNA type in the cervix.  
(2) The ICC samples with unknown tumor DNA status were excluded from the analysis in table 3A. 
(3) Positive for any Ab specific to the given HPV type. 
(4) of women with serum Abs to any Ag of the corresponding HPV type. 
(5) Type-specific HPV DNA positive. 
 
 
 
Figure 1. Detection of IgG in human serum using HPV protein arrays. (A) Detection of IgG Abs in serum from a patient with ICC. Immunoreactivity to the 
positive control EBV EBNA-1 protein, and HPV E4 protein from 4 different HPV types (16, 31, 35, and 45) are detected. (B) and (C) Detection of IgG Abs in sera from 
two women with CIN II/III. Immunoreactivity to HPV16 E4, HPV52 E4 (B) and HPV58E4 (C) as well as EBNA-1 protein, is shown. Dark spots represent the individual 
proteins (HPV Ags and non HPV-related controls in random order) displayed on the arrays after adjusting the raw images to extreme brightness and contrast. Positive 
spots (with diffused signal) are labeled. 
 
Cross-reactivity of serologic responses 
We determined the prevalence of Abs against 
homologous Ags (i.e. all E7 Ags) from more than one 
HPV type in all sera (n=234) from the three cervical 
disease groups under investigation (Table 4). Abs 
against L2 were the most cross-reactive, while anti-E1 
Abs were the least cross-reactive. Of sera that had Abs 
against any L2 Ag, 57.7% were positive for L2 from at 
least 6 HPV types. For E1, all 8 women who had 
specific Abs were positive for E1 from only one HPV 
type. 8.1% of all women had Abs to E7 from at least 2 
HPV types. The percentages of sera with 
cross-reactive Abs to at least one other HPV type were 
as follows: E2 (6.3%), E4 (29.0%), E5 (14.3%), E6 
(17.4%), E7 (43.2%), L1 (39.3%), and L2 (73.1%).  
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Table 4. Prevalence of serum Abs to homologous Ags from different HPV types. 
Homologous Abs(1)  E1 E2 E4 E5 E6 E7 L1 L2 
 No.  0 1 7 3 1 10 17 3 
=2 % of total(2)  0.0 0.4 3.0 1.3 0.4 4.3 7.3 1.3 
 % of positive(3) 0.0 6.3 22.6 14.3 4.3 22.7 20.2 11.5 
 No.  0 0 1 0 3 9 9 1 
=3 % of total(2)  0.0 0.0 0.4 0.0 1.3 3.8 3.8 0.4 
 % of positive(3) 0.0 0.0 3.2 0.0 13.0 20.5 10.7 3.8 
 No.  0 0 1 0 0 3 3 0 
=4 % of total(2)  0.0 0.0 0.4 0.0 0.0 1.3 1.3 0.0 
 % of positive(3) 0.0 0.0 3.2 0.0 0.0 6.8 3.6 0.0 
 No.  0 0 0 0 0 0 2 0 
=5 % of total(2) 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 
 % of positive(3) 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.0 
 No.  0 0 0 0 0 1 2 15 
≥6 % of total(2)  0.0 0.0 0.0 0.0 0.0 0.4 0.9 6.4 
 % of positive(3) 0.0 0.0 0.0 0.0 0.0 2.3 2.4 57.7 
(1) Number of homologous Ags from different HPV types to which Abs were detected in sera from all three disease groups (n=234). 
(2) Percentage of women who had Abs to a given Ag from one or more HPV types over the total number of women. 
(3) Percentage of women who had Abs to a given Ag from multiple HPV types over the number of women who had Abs to this Ag from at least one HPV type. 
 
 
Discussion 
There is a clinical need for circulating 
biomarkers that identify high-risk HPV infection for 
early detection and treatment of cervical disease. 
Here, we have used our custom HPV protein 
microarrays, displaying the proteomes of two 
low-risk and ten high-risk HPV types, to characterize 
the diversity of the immune response in cervical 
cancer and in pre-invasive cervical disease. We find 
that 20 – 46% of patients with CIN and ICC have a 
broad range of Abs to HPV early proteins in their sera 
and these biomarkers correlate with disease severity.  
Up to 80% of patients with HPV-associated 
oropharyngeal cancer (HPVOPC) have detectable 
serum HPV16 Abs to E Ags [48-50]. Abs against the 
oncogenic proteins E6 and E7 are also highly specific 
to ICC. As a result, most cervical cancer studies have 
focused on E6, E7, and L1 Abs from HPV16 and 18 
[21, 22, 27, 31]. In the only previous study of Abs to 
entire HPV proteomes using slide-based protein 
microarrays, high levels of Abs were detected against 
E7 but not E6 or L1 in ICC sera, possibly due to the 
difficulty of expressing larger-sized proteins [16]. In 
that study and others [21, 23, 26], no significant 
difference in Ab response between CIN II/III and 
asymptomatic controls was detected.  
While L-specific Abs were detected in serum 
from women in all three groups of cervical disease in 
our study, Abs against any E protein were, as 
expected, more prevalent in ICC and CIN II/III than 
women with CIN 0/I. Anti-E7 Abs were the most 
frequently detected E-Abs, and our data of E7-specific 
Abs in ICC is consistent with previous studies. Using 
ELISA [25, 27, 51] and Luminex bead arrays [22, 52, 
53], anti-E7 Abs were detected in 13 – 53% of women 
with ICC and in ~60% of ICC (and 10% of healthy 
controls) using protein microarrays [16].  
As cervical disease progresses towards 
malignancy, infectious viral particle production 
becomes limited to a small area near the surface of the 
cervical epithelium [54, 55]. E4 plays a role in viral 
synthesis and possibly viral release [56]. The 
expression of E4 in CIN II and III is restricted to this 
subset of cells and is generally lost in ICC [54]. 
Expression of E4 protein in tissue has been proposed 
as an early detection marker [55] but specific serum 
Abs may provide a more convenient detection 
method. Our data show that E4-specific Abs develop 
early in disease progression, with 16 – 17% prevalence 
in both CIN II/III and ICC. Anti-E4 Abs have been 
reported in sera from women with CIN II/III (34%) 
and ICC (29%) [57], which is consistent with our 
findings and the predicted level of E4 expression 
especially in CIN II/III.  
Viral integration into the host genome, with loss 
of E2 expression, is a frequent hallmark of 
HPV-associated cancers, leading to derepression of E6 
and E7 expression. Since E2 Ag is expressed in CIN 
II/III [58], we predicted that E2 Abs would also be 
detected early in CIN II/III. E2-specific Abs were 
detected in both CIN II/III (4.9%) and at higher 
(p<0.05) frequency in ICC (14.5%) but were at low 
prevalence. E2-specific IgG Abs have been reported in 
24% of women with CIN I-III (compared to 13% of 
healthy controls) [59] and in 12% of women with ICC 
(compared to 2% of healthy controls) [28], consistent 
with our data. Since the majority (64%) of patients 
with HPVOPC have Abs against HPV16 E2 [48, 49], 
our data suggest that these two tumor sites may have 
significant differences in viral integration and 
expression of E2 Ag, or exposure of E2 Ag to B cells. In 
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cervical disease, E1 Abs have been reported to have a 
low prevalence (10% and 0.3% in ICC and healthy 
controls, respectively) [28]. We also found an overall 
low prevalence of anti-E1 Abs in cervical disease, as 
opposed to a 60% prevalence in HPVOPCs [48, 49].  
Only a few studies have investigated the 
immune response against multiple HPV types [16, 21, 
28, 31]. Only one study displayed multiple HPV 
proteomes on protein arrays [16] and the others have 
used glutathione S-transferase-based multiplex 
serology to evaluate serum Abs against only E6, E7, 
and L1 Ags from multiple HPV types [28, 31]. The 
question of cross-reactivity of Abs against Ags from 
closely-related viral types has therefore not been 
adequately addressed. We and others have previously 
demonstrated that MAbs raised against specific HPV 
proteins may cross-react with homologous proteins 
from different HPV types due to sequence similarity 
[16, 41]. Here, we detected cross-reactive Abs 
including against the E4 Ag. The E4 ORF is the most 
divergent between HPV types [60]. The range of 
amino acid sequence similarity between E4 from the 
non-HPV16 types detected in the 3 sample sera 
illustrated in Figure 1 and HPV16 E4 is 42 – 59%. It is 
therefore not known if Abs to multiple homologous 
E4 proteins reflect cross-reactivity with conserved 
epitopes or prior multiple HPV infections. We also 
observed Abs against L2 from at least 6 HPV types in 
57.7% of women who had L2-specific Abs (Table 4), 
which likely indicates cross-reactivity, given the high 
(46 – 63%) sequence conservation of the L2 protein, 
and the interest in developing it as a vaccine [61]. Abs 
against L1 from three or more HPV types were also 
detected in 19% of women positive for L1 Abs. This is 
consistent with previously reported L1 
cross-reactivity detected by an HPV16 L1-specific 
MAb [16]. Overall, these data suggest that these HPV 
arrays will have limited utility as surrogate markers 
for HPV typing.  
While not directly compared in this study, the 
signal intensity of Ab binding on the arrays [41] and 
on RAPID ELISA [48, 49] are consistently weaker in 
cervical disease than in HPVOPC (unpublished 
observations). Additionally, despite tissue expression 
of the oncoproteins E6 and E7 in ICC, we and others 
[16, 22, 23] have reported specific serum Abs in less 
than half of the patients, while they are detected in up 
to 75% of HPVOPC cases [48]. Anti-E6 Abs have been 
detected in HPVOPC and cervical cancer cases years 
prior to the establishment of a clinical diagnosis [26, 
50], suggesting these may be useful for early 
detection. The Ab response to the E proteins in high 
grade pre-invasive cervical lesions, however, has been 
difficult to detect in previous studies [16, 23, 26]. Even 
though we detect E-specific Abs in a subset of CIN 
II/III, the frequencies are low. The presence of both 
viral DNA and viral oncoproteins in HPVOPC tumors 
suggest that both cancer sites have similar 
pathogenetic mechanisms [62]. Therefore, it is likely 
that the close proximity of lymphoid tissue in the 
tonsils results in a more potent immune induction in 
HPVOPC compared with cervical disease.  
The lack of infrastructure and resources in 
LMICs hampers large-scale implementation of Pap 
test screening [29, 63, 64]. In low-resource 
environments, visual examination with acetic acid 
(VIA) is an inexpensive alternative [65]. It results in a 
25% reduction in cervical cancer incidence and a 35% 
reduction in cervical cancer mortality after a single 
screen [65, 66], with significant downstaging of 
cervical cancers [66]. However, VIA has low 
sensitivity in women older than 50 years, poor 
reproducibility between operators and it requires 
continuous training and supervision. The absence of 
HPV nucleic acid in the cervix is a good negative 
predictor of cervical disease but HPV testing is not 
recommended for women <30 years old because 
transient infection reduces specificity [9, 67]. In 
pooled analyses, HPV testing is more sensitive (90 – 
95% for CIN II/III) than cervical cytology alone or 
VIA but lacks the specificity (89%) for a reliable 
biomarker [67]. To date, there are no established 
tissue, blood, or vaginal biomarkers other than HPV 
nucleic acid and cytology for CIN II/III in high risk 
patients. Biomarkers such as serology that identify 
high-risk HPV infection and invasive cervical cancers 
(ICC) could have an impact on the screening, 
detection, and treatment of cervical disease. 
Abbreviations  
Abs, antibodies; Ags, antigens; HPV, human 
papillomavirus; ICC, invasive cervical cancer; CIN, 
cervical intraepithelial neoplasia; NAPPA, nucleic 
acid programmable protein arrays; EBNA-1, 
epstein-barr virus nuclear antigen-1. 
Supplementary Material  
Supplementary figure 1. 
http://www.thno.org/v07p3814s1.pdf  
Acknowledgements 
This study was supported by a research grant 
from the Early Detection Research Network (EDRN) 
UO1 CA11734 (K.S.A.), the National Cancer Institute 
1UG3CA211415 (K.S.A.), EDRN Interagency 
Agreement Y1-CN-0101-01 (E.R.U) and 
Y1-CN-5005-01 (E.R.U.), and Arizona State University 
institutional funds (K.S.A.). The authors thank 
Jennifer Van Duine, Lisa Miller, Eric Pacheco, and 
Tirinder Bharaj for technical assistance. We thank Dr. 
 Theranostics 2017, Vol. 7, Issue 16 
 
 
http://www.thno.org 
3822 
Arvind Varsani for providing the HPV image for the 
graphical abstract. The findings and conclusions in 
this report are those of the authors and do not 
necessarily represent the views of the funding 
agencies or the official position of the Centers for 
Disease Control and Prevention. 
Competing Interests 
Dr. Anderson is a consultant and has stock 
options with Provista Diagnostics, is a founder of 
FlexBioTech, and is on institutional patent 
submissions for HPV serologic testing. Other authors 
report no conflicts. 
References 
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of 
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 
127:2893-2917. 
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer 
incidence and mortality worldwide: sources, methods and major patterns in 
GLOBOCAN 2012. Int J Cancer. 2015; 136:E359-386. 
3. Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine 
after loop electrosurgical excision procedure effective in preventing recurrence 
in patients with high-grade cervical intraepithelial neoplasia (CIN2–3)? 
Gynecologic Oncology. 2013; 130:264-268. 
4. Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of 
HPV After Introduction of the Vaccination Program in the United States. 
Pediatrics. 2016; 137:e20151968. 
5. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus 
and cervical cancer. Lancet. 2013; 382:889-899. 
6. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. 
Prevalence of HPV infection among females in the United States. JAMA. 2007; 
297:813-819. 
7. Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER. 
Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United 
States: National Health and Nutrition Examination Survey 2003-2004. J Infect 
Dis. 2009; 200:1059-1067. 
8. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV 
infection: unresolved issues. Nat Rev Cancer. 2007; 7:11-22. 
9. Goodman A. HPV testing as a screen for cervical cancer. BMJ. 2015; 350:h2372. 
10. Vicus D, Sutradhar R, Lu Y, Elit L, Kupets R, Paszat L, et al. The association 
between cervical cancer screening and mortality from cervical cancer: a 
population based case-control study. Gynecol Oncol. 2014; 133:167-171. 
11. Vicus D, Sutradhar R, Lu Y, Kupets R, Paszat L, Ontario Cancer Screening 
Research N. Association between cervical screening and prevention of 
invasive cervical cancer in Ontario: a population-based case-control study. Int 
J Gynecol Cancer. 2015; 25:106-111. 
12. Soost HJ, Lange HJ, Lehmacher W, Ruffing-Kullmann B. The validation of 
cervical cytology. Sensitivity, specificity and predictive values. Acta Cytol. 
1991; 35:8-14. 
13. Qiao Y-l, Sellors JW, Eder PS, Bao Y-p, Lim JM, Zhao F-h, et al. A new 
HPV-DNA test for cervical-cancer screening in developing regions: a 
cross-sectional study of clinical accuracy in rural China. Lancet Oncol. 2008; 
9:929-936. 
14. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al. The biology 
and life-cycle of human papillomaviruses. Vaccine. 2012; 30 Suppl 5:F55-70. 
15. Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, et al. 
Immunologic responses following administration of a vaccine targeting 
human papillomavirus Types 6, 11, 16, and 18. Vaccine. 2006; 24:5571-5583. 
16. Luevano M, Bernard HU, Barrera-Saldana HA, Trevino V, Garcia-Carranca A, 
Villa LL, et al. High-throughput profiling of the humoral immune responses 
against thirteen human papillomavirus types by proteome microarrays. 
Virology. 2010; 405:31-40. 
17. Stanley M. HPV - immune response to infection and vaccination. Infect Agent 
Cancer. 2010; 5:19. 
18. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, et al. 
Comparison of human papillomavirus types 16, 18, and 6 capsid antibody 
responses following incident infection. J Infect Dis. 2000; 181:1911-1919. 
19. Dillner J. The serological response to papillomaviruses. Semin Cancer Biol. 
1999; 9:423-430. 
20. Bierl C, Karem K, Poon AC, Swan D, Tortolero-Luna G, Follen M, et al. 
Correlates of cervical mucosal antibodies to human papillomavirus 16: results 
from a case control study. Gynecol Oncol. 2005; 99:S262-268. 
21. Gutierrez-Xicotencatl L, Salazar-Pina DA, Pedroza-Saavedra A, 
Chihu-Amparan L, Rodriguez-Ocampo AN, Maldonado-Gama M, et al. 
Humoral Immune Response Against Human Papillomavirus as Source of 
Biomarkers for the Prediction and Detection of Cervical Cancer. Viral 
Immunol. 2016; 29:83-94. 
22. Reuschenbach M, Waterboer T, Wallin KL, Einenkel J, Dillner J, Hamsikova E, 
et al. Characterization of humoral immune responses against p16, p53, HPV16 
E6 and HPV16 E7 in patients with HPV-associated cancers. Int J Cancer. 2008; 
123:2626-2631. 
23. Stanley M. Antibody reactivity to HPV E6 and E7 oncoproteins and early 
diagnosis of invasive cervical cancer. Am J Obstet Gynecol. 2003; 188:3-4. 
24. Ravaggi A, Romani C, Pasinetti B, Tassi RA, Bignotti E, Bandiera E, et al. 
Correlation between serological immune response analyzed by a new ELISA 
for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer 
patients. Arch Virol. 2006; 151:1899-1916. 
25. Silins I, Avall-Lundqvist E, Tadesse A, Jansen KU, Stendahl U, Lenner P, et al. 
Evaluation of antibodies to human papillomavirus as prognostic markers in 
cervical cancer patients. Gynecol Oncol. 2002; 85:333-338. 
26. Lehtinen M, Pawlita M, Zumbach K, Lie K, Hakama M, Jellum E, et al. 
Evaluation of antibody response to human papillomavirus early proteins in 
women in whom cervical cancer developed 1 to 20 years later. Am J Obstet 
Gynecol. 2003; 188:49-55. 
27. Achour M, Zeghal D, Kochbati L, Kahla S, Zouari F, Maalej M, et al. Antibody 
response for L1, E6, E7 HPV 16, and HPV 18 antigens in Tunisian women with 
cervical cancer. J Immunoassay Immunochem. 2009; 30:82-96. 
28. Combes JD, Pawlita M, Waterboer T, Hammouda D, Rajkumar T, Vanhems P, 
et al. Antibodies against high-risk human papillomavirus proteins as markers 
for invasive cervical cancer. Int J Cancer. 2014; 135:2453-2461. 
29. Kontostathi G, Zoidakis J, Anagnou NP, Pappa KI, Vlahou A, Makridakis M. 
Proteomics approaches in cervical cancer: focus on the discovery of 
biomarkers for diagnosis and drug treatment monitoring. Expert Rev 
Proteomics. 2016; 13:731-745. 
30. Zumbach K, Kisseljov F, Sacharova O, Shaichaev G, Semjonova L, Pavlova L, 
et al. Antibodies against oncoproteins E6 and E7 of human papillomavirus 
types 16 and 18 in cervical-carcinoma patients from Russia. Int J Cancer. 2000; 
85:313-318. 
31. Waterboer T, Sehr P, Michael KM, Franceschi S, Nieland JD, Joos TO, et al. 
Multiplex human papillomavirus serology based on in situ-purified 
glutathione s-transferase fusion proteins. Clin Chem. 2005; 51:1845-1853. 
32. Ramachandran N, Hainsworth E, Bhullar B, Eisenstein S, Rosen B, Lau AY, et 
al. Self-assembling protein microarrays. Science. 2004; 305:86-90. 
33. Ramachandran N, Raphael JV, Hainsworth E, Demirkan G, Fuentes MG, Rolfs 
A, et al. Next-generation high-density self-assembling functional protein 
arrays. Nat Methods. 2008; 5:535-538. 
34. Montor WR, Huang J, Hu Y, Hainsworth E, Lynch S, Kronish JW, et al. 
Genome-wide study of Pseudomonas aeruginosa outer membrane protein 
immunogenicity using self-assembling protein microarrays. Infect Immun. 
2009; 77:4877-4886. 
35. Prados-Rosales R, Carreno LJ, Batista-Gonzalez A, Baena A, Venkataswamy 
MM, Xu J, et al. Mycobacterial membrane vesicles administered systemically 
in mice induce a protective immune response to surface compartments of 
Mycobacterium tuberculosis. MBio. 2014; 5:e01921-01914. 
36. Bian X, Wasserfall C, Wallstrom G, Wang J, Wang H, Barker K, et al. Tracking 
the Antibody Immunome in Type 1 Diabetes Using Protein Arrays. J Proteome 
Res. 2016. 
37. Miersch S, Bian X, Wallstrom G, Sibani S, Logvinenko T, Wasserfall CH, et al. 
Serological autoantibody profiling of type 1 diabetes by protein arrays. J 
Proteomics. 2013; 94:486-496. 
38. Anderson KS, Cramer DW, Sibani S, Wallstrom G, Wong J, Park J, et al. 
Autoantibody signature for the serologic detection of ovarian cancer. J 
Proteome Res. 2015; 14:578-586. 
39. Katchman BA, Barderas R, Alam R, Chowell D, Field MS, Esserman LJ, et al. 
Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast 
cancers. PROTEOMICS – Clinical Applications. 2016; 10:720-731. 
40. Wang J, Figueroa JD, Wallstrom G, Barker K, Park JG, Demirkan G, et al. 
Plasma Autoantibodies Associated with Basal-like Breast Cancers. Cancer 
Epidemiol Biomarkers Prev. 2015; 24:1332-1340. 
41. Ewaisha R, Meshay I, Resnik J, Katchman BA, Anderson KS. Programmable 
protein arrays for immunoprofiling HPV-associated cancers. PROTEOMICS. 
2016; 16:1215-1224. 
42. Wong J, Sibani S, Lokko NN, LaBaer J, Anderson KS. Rapid detection of 
antibodies in sera using multiplexed self-assembling bead arrays. J Immunol 
Methods. 2009; 350:171-182. 
43. Rajeevan MS, Swan DC, Nisenbaum R, Lee DR, Vernon SD, Ruffin MT, et al. 
Epidemiologic and viral factors associated with cervical neoplasia in 
HPV-16-positive women. Int J Cancer. 2005; 115:114-120. 
44. Anderson KS, Sibani S, Wallstrom G, Qiu J, Mendoza EA, Raphael J, et al. 
Protein microarray signature of autoantibody biomarkers for the early 
detection of breast cancer. Journal of proteome research. 2011; 10:85-96. 
45. Wang J, Barker K, Steel J, Park J, Saul J, Festa F, et al. A versatile protein 
microarray platform enabling antibody profiling against denatured proteins. 
Proteomics Clin Appl. 2013; 7:378-383. 
46. Qiu J, LaBaer J. Nucleic acid programmable protein array a just-in-time 
multiplexed protein expression and purification platform. Methods Enzymol. 
2011; 500:151-163. 
47. Unger ER, Vernon SD, Lee DR, Miller DL, Reeves WC. Detection of human 
papillomavirus in archival tissues. Comparison of in situ hybridization and 
polymerase chain reaction. J Histochem Cytochem. 1998; 46:535-540. 
 Theranostics 2017, Vol. 7, Issue 16 
 
 
http://www.thno.org 
3823 
48. Anderson KS, Dahlstrom KR, Cheng JN, Alam R, Li G, Wei Q, et al. HPV16 
antibodies as risk factors for oropharyngeal cancer and their association with 
tumor HPV and smoking status. Oral Oncol. 2015; 51:662-667. 
49. Anderson KS, Gerber JE, D'Souza G, Pai SI, Cheng JN, Alam R, et al. Biologic 
predictors of serologic responses to HPV in oropharyngeal cancer: The 
HOTSPOT study. Oral Oncol. 2015; 51:751-758. 
50. Kreimer AR, Johansson M, Waterboer T, Kaaks R, Chang-Claude J, Drogen D, 
et al. Evaluation of human papillomavirus antibodies and risk of subsequent 
head and neck cancer. J Clin Oncol. 2013; 31:2708-2715. 
51. Tjiong MY, Zumbach K, Schegget JT, van der Vange N, Out TA, Pawlita M, et 
al. Antibodies against human papillomavirus type 16 and 18 E6 and E7 
proteins in cervicovaginal washings and serum of patients with cervical 
neoplasia. Viral Immunol. 2001; 14:415-424. 
52. Castellsague X, Pawlita M, Roura E, Margall N, Waterboer T, Bosch FX, et al. 
Prospective seroepidemiologic study on the role of Human Papillomavirus 
and other infections in cervical carcinogenesis: evidence from the EPIC cohort. 
Int J Cancer. 2014; 135:440-452. 
53. Lang Kuhs KA, Anantharaman D, Waterboer T, Johansson M, Brennan P, 
Michel A, et al. Human Papillomavirus 16 E6 Antibodies in Individuals 
without Diagnosed Cancer: A Pooled Analysis. Cancer Epidemiol Biomarkers 
Prev. 2015; 24:683-689. 
54. Doorbar J. Molecular biology of human papillomavirus infection and cervical 
cancer. Clin Sci (Lond). 2006; 110:525-541. 
55. Griffin H, Wu Z, Marnane R, Dewar V, Molijn A, Quint W, et al. E4 antibodies 
facilitate detection and type-assignment of active HPV infection in cervical 
disease. PLoS One. 2012; 7:e49974. 
56. Doorbar J. The E4 protein; structure, function and patterns of expression. 
Virology. 2013; 445:80-98. 
57. Pedroza-Saavedra A, Cruz A, Esquivel F, De La Torre F, Berumen J, Gariglio P, 
et al. High prevalence of serum antibodies to Ras and type 16 E4 proteins of 
human papillomavirus in patients with precancerous lesions of the uterine 
cervix. Arch Virol. 2000; 145:603-623. 
58. Xue Y, Bellanger S, Zhang W, Lim D, Low J, Lunny D, et al. HPV16 E2 is an 
immediate early marker of viral infection, preceding E7 expression in 
precursor structures of cervical carcinoma. Cancer Res. 2010; 70:5316-5325. 
59. Marais D, Rose RC, Williamson AL. Age distribution of antibodies to human 
papillomavirus in children, women with cervical intraepithelial neoplasia and 
blood donors from South Africa. J Med Virol. 1997; 51:126-131. 
60. Bell I, Martin A, Roberts S. The E1^E4 protein of human papillomavirus 
interacts with the serine-arginine-specific protein kinase SRPK1. J Virol. 2007; 
81:5437-5448. 
61. Karanam B, Jagu S, Huh WK, Roden RB. Developing vaccines against minor 
capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol. 
2009; 87:287-299. 
62. Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, et al. Distinct 
risk factor profiles for human papillomavirus type 16-positive and human 
papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 
2008; 100:407-420. 
63. Wentzensen N, von Knebel Doeberitz M. Biomarkers in cervical cancer 
screening. Dis Markers. 2007; 23:315-330. 
64. Wright TC, Jr. HPV DNA testing for cervical cancer screening. FIGO 26th 
Annual Report on the Results of Treatment in Gynecological Cancer. Int J 
Gynaecol Obstet. 2006; 95 Suppl 1:S239-246. 
65. Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, 
Shanthakumari S, et al. Effect of visual screening on cervical cancer incidence 
and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet. 2007; 
370:398-406. 
66. Shastri SS, Mittra I, Mishra GA, Gupta S, Dikshit R, Singh S, et al. Effect of VIA 
screening by primary health workers: randomized controlled study in 
Mumbai, India. J Natl Cancer Inst. 2014; 106:dju009. 
67. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence 
regarding human papillomavirus testing in secondary prevention of cervical 
cancer. Vaccine. 2012; 30 Suppl 5:F88-99. 
 
 
